ARS Pharmaceuticals (SPRY) said Monday it has granted ALK-Abello exclusive rights to commercialize neffy nasal spray, its emergency treatment for Type I allergic reactions, in Europe, Canada, and other territories outside the US.
Under the licensing agreement, ARS Pharmaceuticals said it will receive $145 million upfront and up to $320 million in milestone payments, along with royalties.
ARS will manufacture and supply neffy to ALK-Abello and retain US rights while there are no changes to partnerships for neffy in Japan, China, Australia and New Zealand, ARS Pharmaceuticals added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。